Recent Posts

Honored to be recognized by peers as a “2022 Top Doctor”. Very grateful to work with so many talented colleagues towards the collective goals of highest quality care, clinical research and cutting edge treatments…. #ophthalmology #medicine #clinicalresearch https://t.co/tiDBGAgGqS

Honored to be recognized by peers as a “2022 Top Doctor”. Very grateful to work with so many talented colleagues towards the collective goals of highest quality care, clinical research and cutting edge treatments…. #ophthalmology #medicine #clinicalresearch https://t.co/tiDBGAgGqS. Check out more on Thomas Ciulla’s website.

RT @ThomasCiullaMD: Just published: “Aging Effects on Optic Nerve Neurodegeneration” Optic nerve neurodegeneration can serve as a model for…

RT @ThomasCiullaMD: Just published: “Aging Effects on Optic Nerve Neurodegeneration” Optic nerve neurodegeneration can serve as a model for…. Check out more on Thomas Ciulla’s website.

RT @ThomasCiullaMD: Just published in this month’s Retinal Physician issue focused on gene therapy. We are fortunate to witness such treme…

RT @ThomasCiullaMD: Just published in this month’s Retinal Physician issue focused on gene therapy.

We are fortunate to witness such treme…. Check out more on Thomas Ciulla’s website.

Looking forward to presenting at @Eyecelerator during this week’s annual meeting…

[ad_1] Looking forward to presenting at @Eyecelerator during this week’s annual meeting of the @aao_ophth! Now, #clinicaltrials involving suprachoroidal delivery include a tyrosine kinase inhibitor, a corticosteroid, a #genetherapy & a virus-like drug conjugate https://t.co/qgyOQb2YzJ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main 

RT @eyetubenet: Are you attending the #AAO2022 Annual Meeting?! Join us in-pers…

[ad_1] RT @eyetubenet: Are you attending the #AAO2022 Annual Meeting?! Join us in-person or virtually for a #CME Symposium. ‘Into the Suprachoroi… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Recent article @RetinalPhys: #Suprachoroidal Drug Delivery T…

[ad_1]
RT @ThomasCiullaMD: Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is cl…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Our paper, “Longer-Term Anti-VEGF Therapy Outcomes in Neova…

[ad_1] RT @ThomasCiullaMD: Our paper, https://t.co/vztXKnKI4P “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO-Related M… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @JCRnEDITORS: Suprachoroidal delivery enables targeting, localization and dur…

[ad_1] RT @JCRnEDITORS: Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions. | Thomas A. Ciulla @… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ScienceCrisp: REVIEW “Advancements in ocular gene therapy delivery: vectors …

[ad_1]
RT @ScienceCrisp: REVIEW “Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xi…

[ad_1] Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is clinical reality. 4 therapies delivered SC are in #clinicaltrials: a corticosteroid, a TKI, a #genetherapy & a virus-like drug conjugate. https://t.co/iIkyKHNh4r [ad_2] Source by Thomas Ciulla, MD, MBA Return to main